EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/ metastatic urothelial carcinoma (la/mUC) in northern Spain

被引：1
|
作者：
Fernandez-Rodriguez, R. [1 ]
Sagastibelza, N. [2 ]
Pujol Obis, E. [3 ]
Lainez Milagro, N. [4 ]
Sanchez-Escribano, R. [5 ]
Martinez Kareaga, M. [6 ]
Verdun Aguilar, J. A. [7 ]
Arruti Ibarbia, M. [8 ]
Pumares Gonzalez, M. [9 ]
De Portugal Fernandez del Rivero, T. [10 ]
Lacalle, A. [11 ]
Gil Arnaiz, I. [12 ]
Pereira-Elorrieta, A. [13 ]
Duran Martinez, I. [14 ]
机构：
[1] Hosp Univ Cruces, Med Oncol, Baracaldo, Spain
[2] Hosp Donostia, Dept Med Oncol, San Sebastian, Spain
[3] Hosp Clin Univ Lozano Blesa, Med Oncol, Zaragoza, Spain
[4] Hosp Navarra, Med Oncol, Pamplona, Spain
[5] Univ Clin Hosp Valladolid, Med Oncol, Valladolid, Spain
[6] HUA Hosp Univ Araba Txagorritxu, Med Oncol, Vitoria, Spain
[7] Hosp Comarcal Alcaniz, Oncol, Alcaniz, Spain
[8] Hosp Galdakao Usansolo, Med Oncol, Galdakao, Spain
[9] Hosp Univ Burgos HUBU, Med Oncol, Burgos, Spain
[10] Hosp Prov Rodriguez Chamorro, Dept Oncol, Zamora, Spain
[11] Hosp San Pedro, Med Oncol, Logrono, Spain
[12] Hosp Reina Sofia, Med Oncol, Tudela, Spain
[13] IDIVAL Inst Invest Sanitaria Valdecilla, Oncol, Santander, Spain
[14] HUMV Hosp Univ Marques de Valdecilla, Dept Despacho 271, Santander, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2382P
引用
收藏
页码：S1213 / S1213
页数：1
相关论文
共 50 条
  • [21] Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab
    Morgans, Alicia K.
    Sonpavde, Guru P.
    Shih, Vanessa
    Wright, Phoebe
    Hepp, Zsolt
    Willmon, Candice L.
    Chang, Nancy N.
    Mucha, Lisa
    Naga, Sai Sriteja Boppudi
    Powles, Thomas
    CLINICAL GENITOURINARY CANCER, 2024, 23 (01)
  • [22] Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France
    Joly, Florence
    Culine, Stephane
    Roupret, Morgan
    Tricotel, Aurore
    Casarotto, Emilie
    Brice, Sandrine
    Minacori, Rafael
    Vuillet, Marthe
    Thomas, Marie-Catherine
    Leyland, Kirsten
    Upadhyay, Anil
    Munro, Vicki
    Strunz-McKendry, Torsten
    FUTURE ONCOLOGY, 2025, 21 (06) : 665 - 679
  • [23] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Evaluating oncologists' practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma (la/mUC): The US physician PARADIGM study (Part 2).
    Liu, Frank
    Costantino, Halley
    Ike, Chiemeka
    Gupta, Shaloo
    Bhanegaonkar, Abhijeet
    Thakkar, Sheena
    Devgan, Geeta
    Katzenstein, Howard
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la/mUC): A systematic literature review
    Wilke, T.
    Zhang, L.
    Hubscher, E.
    Musat, M. G.
    Harricharan, S.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1345 - S1345
  • [26] Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma
    Omland, Lise H.
    Joensen, Ulla N.
    Toft, Birgitte G.
    Lund, Cecilia M.
    Lindberg, Henriette
    Knudsen, Mark B.
    Tolver, Anders
    Suetta, Charlotte
    Pappot, Helle
    ACTA ONCOLOGICA, 2022, 61 (09) : 1036 - 1042
  • [27] Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
    Rosenberg, J.
    Petrylak, D.
    Abidoye, O.
    Van der Heijden, M. S.
    Hofman-Censits, J.
    Necchi, A.
    O'Donnell, P. H.
    Balmanoukian, A.
    Loriot, Y.
    Retz, M.
    Perez-Gracia, J. L.
    Dawson, N. A.
    Balar, A.
    Galsky, M. D.
    Fleming, M. T.
    Powles, T.
    Cui, N.
    Mariathasan, S.
    Fine, G. D.
    Dreicer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S720 - S720
  • [28] AUSTRALI-AVE: Design of a retrospective noninterventional study evaluating real-world patient characteristics and treatment patterns with avelumab in locally advanced or metastatic urothelial cancer (la/mUC) and metastatic Merkel cell carcinoma (mMCC) in Australia
    Ben Tran
    Moujaber, Tania
    Oliveira, Niara
    Shackleton, Mark
    Pook, David
    Franchini, Fanny
    Kouhkamari, Mahsa H.
    Schoeninger, Brittany
    Miles, Alison G.
    Wu, Beilei
    Bennett, Greer
    Varrasso, Annalisa
    Liu, Xiao
    Hoffman, Jason
    Kearney, Mairead
    Xu, Wen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 269 - 270
  • [29] Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
    Crist, Michael
    Iyer, Gopa
    Hsu, Miles
    Huang, William C.
    Balar, Arjun, V
    THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 9
  • [30] Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration
    Alkadimi, Munaf A.
    Aldawoodi, Tamarah A.
    Lucero, Kana T.
    Fierro, Maria E.
    Boyle, Lauren D.
    Mader, Michael J.
    Franklin, Kathleen R.
    Arora, Sukeshi P.
    Nooruddin, Zohra
    ONCOLOGIST, 2024, : 369 - 376
12345